Skip to content

Preventive effect of taurine drug on liver transplant recipients

The protective Effect of taurine on Ischemia-reperfusion syndrom Following liver transplantation

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120731010453N3
Enrollment
100
Registered
2023-03-14
Start date
2023-03-25
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver transplantation. Other complications of liver transplant

Interventions

Intervention 1: Intervention group: One group is given 2 grams of taurine half an hour before surgery. Intervention 2: Control group: Placebo 2 grams of carboxymethyl cellulose is given half an hour b

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients which candidate to liver transplant older than 18 years old

Exclusion criteria

Exclusion criteria: Re-transplantation or simultaneous liver and kidney transplantation Hypersensitivity to taurine

Design outcomes

Primary

MeasureTime frame
Occurrence of reperfusion syndrome during the surgery. Timepoint: During the surgery. Method of measurement: By reviewing patient information.;The required dose of norepinephrine during surgery in order to correct the hypotension. Timepoint: During the surgery. Method of measurement: By reviewing patient information.

Secondary

MeasureTime frame
The functional state of the organ from the time of transplantation to the time of discharge. Timepoint: Duration of hospitalization. Method of measurement: By reviewing patient file information.;Duration of hospitalization in the ICU hospital for CRRT or dialysis. Timepoint: Duration of hospitalization. Method of measurement: By reviewing patient file information.;Mortality rate. Timepoint: Duration of hospitalization. Method of measurement: By reviewing patient file information.;Need for CRRT or dialysis during hospitalization. Timepoint: Duration of hospitalization. Method of measurement: By reviewing patient file information.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojtaba Shafiekhani

Shiraz University of Medical Sciences

mojtabashafiekhani@gmail.com+98 71 3242 4255

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026